Clinical trials: Renal Carcinoma
Renal Cell Carcinoma (RCC), Renal Function Abnormal
Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy
It is demonstrated that remote ischemic preconditioning can alleviate the degree of acute renal injury on the operated side in patients undergoing partial nephrectomy.
- Trial name
- NCT07497958
- Testing
- Ischemic preconditioning, NO ischemic preconditioning
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Sun Yat-sen University
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Cancer
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell…
- Trial name
- NCT02684006
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736), Sunitinib
- Where
- 270 sites in United States, Australia and 19 more
- Volunteers
- 886 people
- Sponsor
- Pfizer
Renal Cell Carcinoma Metastatic
A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
This open-label Phase 1 study will evaluate the safety, tolerability, PK characteristics and preliminarily efficacy of JMKX003948 tablets in patients with renal cell carcinoma.
- Trial name
- NCT06321250
- Testing
- JMKX003948
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jemincare
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Metastatic Renal Cell Carcinoma
Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer
The rise of oral targeted therapies favors outpatient care of cancer patients but exposes them to new risks compared to the injectable chemotherapy in the hospital: non-adherence to treatment, inappropriate management of side…
- Trial name
- PRISM care (NCT02849535)
- Testing
- PRISM care program
- Where
- 12 sites in France
- Volunteers
- 190 people
- Sponsor
- Hospices Civils de Lyon
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
ccRCC, Clear Cell Renal Cell Carcinoma
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms
- Trial name
- NCT05119335
- Testing
- Oral NKT2152
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- NiKang Therapeutics, Inc.
Melanoma, Renal Cell Carcinoma
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
The purpose of this study is to collect prospective data for use as a comparator for future subsequent studies attempting to increase the efficacy or reduce the toxicity of gamma knife radiosurgery.
- Conditions
- Melanoma, Renal Cell Carcinoma, Sarcoma, Breast Cancer
- Trial name
- NCT02005614
- Testing
- Gamma Knife Radiosurgery
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Yale University
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation
Recurrent Renal Cell Cancer
Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer
This randomized pilot trial studies clamped or unclamped surgery in treating patients with kidney cancer. Unclamped surgery for kidney cancer may have fewer side effects
- Trial name
- NCT01547676
- Testing
- robot-assisted laparoscopic surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Southern California
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Glioblastoma Multiforme, Gliosarcoma
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
The purpose of this study is to determine whether the combination of two agents, INC280 and bevacizumab, is safe and effective when administered to patients with Glioblastoma Multiforme (GBM) who have progressed after receiving…
- Conditions
- Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT02386826
- Testing
- INC280, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 65 people
- Sponsor
- SCRI Development Innovations, LLC
Renal Cell Carcinoma
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
CyberKnife Based Radiosurgery is a way to deliver large doses of radiation very accurately to a tumor. The ability of this technology to minimize radiation dose to organs adjacent to the target tumor allows a high dose to be…
- Trial name
- NCT01890590
- Testing
- CyberKnife
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Beth Israel Deaconess Medical Center
Renal Cell Carcinoma
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
This is a phase II open label, single arm study evaluating treatment with pazopanib post sunitinib treatment in 43 patients with metastatic renal cell carcinoma.
- Trial name
- NCT01566747
- Testing
- Pazopanib
- Where
- 9 sites in Ireland, Sweden
- Volunteers
- 43 people
- Sponsor
- Cancer Trials Ireland
Kidney Cancer
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- S0931 (NCT01120249)
- Testing
- everolimus
- Where
- 1,003 sites in United States, Puerto Rico
- Volunteers
- 1,545 people
- Sponsor
- SWOG Cancer Research Network
Immune Checkpoint Inhibitors-induced Colitis, Advanced Melanoma Skin Cancer, Non-small Cell Lung Carcinoma, Kidney Adenocarcinoma
Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our results, and due to the rarity of this condition.
- Conditions
- Immune Checkpoint Inhibitors-induced Colitis, Advanced Melanoma Skin Cancer, Non-small Cell Lung Carcinoma, Kidney Adenocarcinoma, Ileo-colitis, Immune Mediated-colitis
- Trial name
- NCT06899789
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC).
- Conditions
- Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Metastatic Kidney Carcinoma
- Trial name
- NCT07716735
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Renal Cell
Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma (aRCC) Receiving Systemic First-line (1st Line) Anti-cancer Treatment Under Daily Routine in Germany: Retrospective Medical Chart Review (RENALISTIC Study).
The purpose of this study is to learn about the treatments used in for advanced renal cell carcinoma as well as effectiveness of these treatments in the real world. Study participants must be: At least 18 years of age or older.
- Trial name
- NCT05534789
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.